Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Marker Therapeutics ( (MRKR) ) is now available.
Marker Therapeutics has announced the treatment of the first patient in its Off-the-Shelf (OTS) program, which aims to accelerate the time to treatment using Multi-Antigen Recognizing (MAR) T cells. The Phase 1 RAPID study showed that the OTS product was well tolerated, with no treatment-related adverse events, and is initially being tested in patients with acute myeloid leukemia or myelodysplastic syndromes. This program is expected to provide a faster and more accessible treatment option, potentially expanding to other indications and supported by non-dilutive funding from the FDA, NIH, and CPRIT.
The most recent analyst rating on (MRKR) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Marker Therapeutics stock, see the MRKR Stock Forecast page.
Spark’s Take on MRKR Stock
According to Spark, TipRanks’ AI Analyst, MRKR is a Neutral.
Marker Therapeutics is positioned in the biotechnology industry, characterized by high potential but also significant risks. The company exhibits strong revenue growth but faces challenges with profitability and cash flow. Technical indicators present a mixed outlook, with some potential for price reversals. The valuation reflects typical industry dynamics, favoring growth over profitability. Investors should be cautious, focusing on the company’s ability to manage cash flow and improve operational efficiencies to support future growth.
To see Spark’s full report on MRKR stock, click here.
More about Marker Therapeutics
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company that focuses on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
Average Trading Volume: 2,010,457
Technical Sentiment Signal: Strong Sell
Current Market Cap: $12.36M
For detailed information about MRKR stock, go to TipRanks’ Stock Analysis page.